Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study

BACKGROUND: No standard therapies beyond first line are established for advanced squamous cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth factor receptor (EGFR) inhibition and programmed cell death ligand (PD-(L))1 blockade in patients with previously treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lonardi, Sara, Prete, Alessandra Anna, Morano, Federica, Messina, Marco, Formica, Vincenzo, Corsi, Domenico Cristiano, Orciuolo, Corrado, Frassineti, Giovanni Luca, Zampino, Maria Giulia, Casagrande, Mariaelena, Masi, Gianluca, Ronzoni, Monica, Scartozzi, Mario, Buonadonna, Angela, Mosconi, Stefania, Ratti, Margherita, Sartore-Bianchi, Andrea, Tamburini, Emiliano, Prisciandaro, Michele, Bergamo, Francesca, Spada, Massimiliano, Corallo, Salvatore, Vettore, Valentina, Loupakis, Fotios, Fassan, Matteo, Del Bianco, Paola, Zagonel, Vittorina, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611452/
https://www.ncbi.nlm.nih.gov/pubmed/34815354
http://dx.doi.org/10.1136/jitc-2021-002996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611452/
https://www.ncbi.nlm.nih.gov/pubmed/34815354
http://dx.doi.org/10.1136/jitc-2021-002996

Ejemplares similares